Zosano Pharma Announces New Executive Appointment and Management Change
22 9월 2015 - 9:46AM
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage specialty
pharmaceutical company that has developed a proprietary transdermal
microneedle patch system to deliver drug formulations through the
skin, today announced management changes reflecting the evolution
of the business from a R&D-oriented company to a commercially
focused organization as it prepares for completion of the Phase 2
study for ZP-Glucagon in September and of the Phase 1 study for its
ZP-Triptan product candidate by the end of 2015.
Konstantinos Alataris, Ph.D., has been appointed to the newly
created role of President and Chief Operating Officer, and will
join the company on September 21, 2015. Zosano has created this
position to broaden its leadership base as the company's pipeline
of drug candidates advances into later-stage clinical
development.
Pete Daddona, Ph.D., Chief Scientific Officer and Executive Vice
President, R&D will retire from the company, effective December
31, 2015. He will serve as a scientific advisor to Zosano for a
period of one year after his retirement and will continue to guide
the company's R&D strategy.
"Konstantinos brings extensive experience as an executive and
leader in the healthcare field to Zosano," said CEO Vikram Lamba.
"He successfully built the company he founded, Nevro, where he took
the company's product through research and clinical development to
successful commercialization, an experience that will be extremely
valuable as Zosano prepares for pivotal studies and future
commercialization of its lead product candidates. We are extremely
thankful to Pete for his contributions in bringing the technology
to this stage and will continue to benefit from his guidance as a
scientific advisor as we prepare the company for future product
commercialization."
Dr. Alataris was the Founder and held the roles of President,
Chief Executive Officer and Chief Commercial Officer of Nevro Corp.
(NYSE:NVRO), a medical device company that has developed an
innovative, evidence-based neuromodulation platform for the
treatment of chronic pain. At Nevro, Dr. Alataris built the
business from product development to successful commercialization.
He was responsible for negotiating complex clinical development and
regulatory paths in neurological disorders both in the United
States and internationally, resulting in regulatory approved
marketed products. Following Nevro, Dr. Alataris served as
Executive Chairman of the Board of Directors at IRRAS AB and Head
of Digital Healthcare Strategy at mc10. Prior to Nevro, Dr.
Alataris was a Vice President at Bay City Capital, a healthcare
focused venture capital firm based in San Francisco. He holds
Master's degrees in Electrical Engineering and Business and a Ph.D.
in Bioengineering from the University of Southern California.
About Zosano Pharma
Zosano Pharma Corporation is a clinical-stage specialty
pharmaceutical company that has developed a proprietary transdermal
microneedle patch system to deliver drug formulations through the
skin for the treatment of a variety of indications. Zosano Pharma's
microneedle patch system offers rapid onset, consistent drug
delivery, improved ease of use and room-temperature stability,
benefits that the company believes often are unavailable using oral
formulations or injections. Zosano Pharma's microneedle patch
system has the potential to deliver numerous medications for a wide
variety of indications in commercially attractive markets. It has
been tested in more than 400 patients with over 30,000 patches
successfully applied to humans in Phase 1 and Phase 2 clinical
studies. Learn more at www.zosanopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding
expected clinical activities and other future events. Readers are
urged to consider statements that include the words "may," "will,"
"would," "could," "should," "might," "believes," "estimates,"
"projects," "potential," "expects," "plans," "anticipates,"
"intends," "continues," "forecast," "designed," "goal,"
"unaudited," "approximately" or the negative of those words or
other comparable words to be uncertain and forward-looking. These
statements are subject to risks and uncertainties that are
difficult to predict and actual outcomes may differ materially.
These include risks and uncertainties, without limitation,
associated with the process of discovering, developing and
commercializing products that are safe and effective for use as
human therapeutics, risks inherent in the effort to build a
business around such products and other risks and uncertainties
described under the heading "Risk Factors" in Zosano Pharma
Corporation's Annual Report on Form 10-K for the year ended
December 31, 2014 filed with Securities and Exchange Commission on
March 26, 2015. Although the company believes that the expectations
reflected in these forward-looking statements are reasonable, it
cannot in any way guarantee that the future results, level of
activity, performance or events and circumstances reflected in
forward-looking statements will be achieved or occur. All
forward-looking statements are based on information currently
available to Zosano Pharma and Zosano Pharma assumes no obligation
to update any such forward-looking statements.
CONTACT: Zosano Contact:
Vikram Lamba
Chief Executive Officer
510-745-1200
Investor Contact:
Paul Chun
Westwicke Partners
858-356-5931
paul.chun@westwicke.com
Media Contact:
Jamie Lacey-Moreira
PressComm PR, LLC
410-299-3310
jamielacey@presscommpr.com
Zosano Pharma (NASDAQ:ZSAN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Zosano Pharma (NASDAQ:ZSAN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024